Partnerships Significantly Extend Company Capabilities
We are collaborating with several world-class research and patient treatment organizations, including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, HonorHealth and Imaging Endpoints. We seek to leverage these valuable relationships with leading experts in the field to continue the development of our current products and explore follow-on opportunities.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) is one of the world’s leading cancer research hospitals. They have served as an investigative site for the MVT-5873 therapeutic antibody Phase 1 trial. MSK is also the key site for the MVT-2163 PET imaging trial. We have sponsored research and service agreements in place to assist with the preclinical development of several additional products.
We have entered into a sponsored research agreement with MSK for the development of novel Chimeric Antigen Receptor (CAR) T-cell therapeutics using antibody targeting sequences derived from MabVax's fully-human antibodies for pancreatic, small cell lung, and other solid tumor cancers. Under the new agreement, we will provide funding to evaluate the efficacy of multiple CAR T-cell products incorporating several different antibody targeting sequences. The research program will evaluate in xenograft models of pancreatic and small cell lung cancer targeting sequences from our leading monoclonal antibody clinical development candidate HuMab-5B1. Multiple CAR T-cell constructs have been created and tested in cell based assays demonstrating utility and warranting continued testing in animal models of pancreatic cancer and other CA19-9 expressing tumors.
We have provided a second set of novel antibody targeting sequences from its clinical and research programs to MSK for development into new CAR T-cell constructs for the treatment of solid tumors. MSK will evaluate the new CAR T-cell constructs and test in both in vitro and in animal models of solid tumors with a goal of completing investigational new drug (IND) enabling pre-clinical studies. The work will be conducted in the laboratory of Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Gene Transfer and Gene Expression at MSK.
MabVax has certain rights to the new CAR T-cell inventions developed during the collaboration, including an exclusive time-limited option to license MSK's rights in such inventions.
Sarah Cannon Research Institute
Sarah Cannon Research Institute is a leading global clinical research organization focused on cancer. Sarah Cannon offers integrated cancer services and cutting–edge therapies. The Sarah Cannon Research Network provides two investigative sites for our MVT-5873 therapeutic antibody trial.
Rockefeller University is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics, and through its unique approach to science has led to some of the world’s most revolutionary contributions to biology and medicine. Rockefeller University is collaborating with MabVax to develop a next-generation HuMab-5B1 antibody. Our collaboration is being conducted under the direction of Jeffery Ravetch, M.D., Ph.D., a world-renowned expert on antibodies.
HonorHealth Research Institute
HonorHealth Research Institute is a unique hybrid of world-class care and groundbreaking clinical trials and research. Leading researchers, physicians and clinical teams work together to bring newly discovered therapies and diagnostic products, as well as provide innovative care and treatments to patients. Through the offerings of its strategic partnerships, the Institute is able to make the greatest impact on the patients’ health and quality of life, by bringing tomorrow’s cures that offer hope to patients today.
HonorHealth is a non-profit health system serving an area of 1.6 million people in the greater Phoenix area. The company encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer center, clinical research, medical education, a foundation and community services.
Imaging Endpoints is a full-service imaging contract research organization providing services to the pharmaceutical, biotech and medical device industries to accelerate their national and international clinical trials. Extensive expertise in imaging allows Imaging Endpoints to perform real-time qualitative and quantitative assessments of both anatomic and physiologic/metabolic imaging modalities in order to better probe the effectiveness of new therapeutics. In addition to its expertise in oncology, Imaging Endpoints has expertise in neurological, musculoskeletal and cardiovascular radiologic sciences, and experience in all phases of clinical trials from preclinical through Phase 3 and post-market studies.
Contact us if you have questions about our company, antibody based therapeutics or any other questions or comments.